European Consortium for Systematic Stem Cell Biology (EuroSyStem)


At a Glance
  • Status: Completed Consortium
  • Year Launched: 2008
  • Initiating Organization: European Commission Sixth Framework Programme (FP6)
  • Initiator Type: Government
  • No disease focus

Abstract

The European Consortium for Systematic Stem Cell Biology (EuroSyStem) brought together elite European research teams to create a unique and world-leading program in fundamental stem cell biology. The project goal was to interlink complementary biological and computational expertise to drive the generation of new knowledge on the characteristics of normal and abnormal stem cells.

Mission

EuroSyStem concentrated on illuminating the molecular circuitry governing the decision between self-renewal and commitment to differentiation. By measuring and modeling stem cell properties and behavior, it paved the way for application of systems methodology. It mined and exploited information from studies and screens in model organisms, but its primary focus was the paradigmatic mammalian stem cell systems — hematopoiesis and epithelia in vivo, and embryonic and neural stem cells in vitro.

EuroSyStem cross-evaluated between systems issues of cellular hierarchy, signaling, epigenetics, dysregulation, and plasticity. Microenvironmental perturbation, asymmetric division, and transcriptional regulation were considered in a cross-cutting, mechanism-centered work package.
 
Its multidisciplinary approach included transgenesis, real-time imaging, multi-parameter flow cytometry, transcriptomics, ribonucleic acid (RNA) interference, proteomics, and single-cell methodologies.
Small to medium-sized enterprises (SMEs) contributed to the development of enhanced-resolution quantitative technologies. A platform work package provided new computational tools and database resources, enabling implementation of novel analytical and modeling approaches. EuroSyStem engaged with and provided a focal point for the European stem cell research community. The focused collaborations within the EuroSyStem research project were augmented by federating the best new independent European investigators working in different tissues and organisms.

Consortium History

March 2008: Project start
August 2012: Project end

Financing

The total cost was €16.0 million, of which the European Union contributed €12 million.  

Impact/Accomplishment

EuroSyStem set and achieved the following major objectives during its four years:

Points of Contact

Jenny Walsham
Project Manager

Jo Butler
Planning and Communications Assistant
          
For project and events inquiries, contact the Project Office:
phone: +44 (0) 1223 760 288
fax: +44 (0) 1223 760 241
email: eurosystem-office@cscr.cam.ac.uk

For press inquiries, contact the Communications Officer:
Cathy Southworth
Communications Officer
phone: +44 (0) 131 651 9508
fax: +44 (0) 131 651 9501
email: eurosystem-comms@ed.ac.uk

Sponsors & Partners

Dresden University of Technology

Ecole Polytechnique Federale de Lausanne

European Institute of Oncology

German Cancer Research Institute

Hemlmholtz Centre Muenchen

Hospital San Raffaele

IMBA – Institute for Biotechnology

Institut de genetique et de biologie moleculaire et cellulaire (IGCCM)

Institut Pasteur

Karolinska Institute

Lund University

Netherlands Cancer Institute

Netherlands Institute for Developmental Biology

Oxford Gene Technology

Universita degli Studi di Milano

University Groningen Medical Centre

University of Cambridge

University of Edinburgh

University of Leipzig

University of Oxford


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.